BPA Call 36C24626A0027-36C24626N0890
Award Date 8/20/26
Potential Completion Date 8/19/27
Potential Value $4.5M
Federal Agency
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
Set-Aside Type
Not listed Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bedford, MA 01730, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 12 issued a delivery order to Progenics Pharmaceuticals Inc. on September 1, 2025, with a ceiling value of $2,959,150.40 for PYLARIFY (piflufolastat F-18), a radiopharmaceutical diagnostic imaging agent, with an ultimate completion date of August 31, 2027. The order is issued under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Progenics, a division of Lantheus Medical Imaging, Inc., is the sole authorized manufacturer of PYLARIFY....
- Veterans Integrated Service Network 22 issued a $180,436 delivery order to Progenics Pharmaceuticals Inc. on July 27, 2026, for supply of PYLARIFY (piflufolastat F-18), a radiopharmaceutical diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection. The order is issued under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). Place of performance is Bedford, MA. The order is priced firm fixed-price with an ultimate completion date of...
- Veterans Integrated Service Network 12 issued a $2,959,150.40 delivery order to Progenics Pharmaceuticals Inc. on May 1, 2026, for PYLARIFY (piflufolastat F-18) prostate imaging radiopharmaceuticals under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The order is firm fixed-price with no set-aside designation and extends through April 30, 2030. Place of performance is Bedford, MA. PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography scans...
- Veterans Integrated Service Network 21 issued a BPA call to Progenics Pharmaceuticals Inc. for 480 doses of PYLARIFY (piflufolastat F-18) with a ceiling value of $1,734,185.60 under a total small business set-aside, with an award date of October 1, 2025. The call covers the period January 1, 2025 through December 31, 2025, with ultimate completion by September 26, 2026. PYLARIFY is a radioactive diagnostic imaging agent used in positron emission tomography scans for detection and localization of...
- The Department of Veterans Affairs, Veterans Integrated Service Network 8, awarded a Blanket Purchase Agreement (BPA) call to Progenics Pharmaceuticals Inc. (a division of Lantheus Medical Imaging, Inc.) on January 1, 2026, for the supply of PYLARIFY Injection with a ceiling value of $1.25M and an ultimate completion date of December 31, 2027. This is a firm fixed-price contract with no set-aside designation issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., received a firm fixed-price blanket purchase agreement (BPA) call valued at $1.335 million from Veterans Integrated Service Network (VISN) 8 for PYLARIFY Injection, with a completion date of December 31, 2025. PYLARIFY (piflufolastat F-18) is a radiopharmaceutical diagnostic imaging agent used in positron emission tomography (PET) scans for the detection and localization of prostate cancer, supporting...
- Veterans Integrated Service Network 21 issued a BPA call to Progenics Pharmaceuticals Inc. under a Total Small Business set-aside on October 1, 2023, with a ceiling value of $864,884.08 for the period October 1, 2023 through September 30, 2024. The call requires delivery of PYLARIFY (piflufolastat F-18), a radiopharmaceutical diagnostic imaging agent used in positron emission tomography scans for prostate cancer detection and localization. Performance occurs at North Billerica, Massachusetts....
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a $599,047.52 firm fixed-price delivery order by Veterans Integrated Service Network 5 on February 1, 2026, for PYLARIFY (piflufolastat F-18) injection radiopharmaceuticals. The contract, with an ultimate completion date of March 1, 2026, contains no set-aside designation and represents performance at the company's facility in Bedford, Massachusetts. This delivery order falls under the...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging Inc., was awarded a delivery order valued at $260,227.84 by Veterans Integrated Service Network 15 on October 22, 2024, for the supply of PYLARIFY (piflufolastat F-18) radiopharmaceutical injections. This firm fixed-price delivery order carries no set-aside designation and is issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) master contract. The contract is scheduled for ultimate...
- Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., was awarded a delivery order valued at $3.6 million by Veterans Integrated Service Network 16 on July 14, 2025, for the supply of F-18 Piflufolastat (PYLARIFY) unit doses. This contract, which extends through June 30, 2029, utilizes a firm fixed-price structure with no set-aside designation and represents performance under the parent Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The...